Table 2.
Patients reporting mild, moderate or severe treatment-related adverse events during treatment with lanreotide autogel
| Organ system | Severe | Moderate | Mild | Total |
|---|---|---|---|---|
| Any |
1 (3.3) |
8 (26.7) |
17 (56.7) |
19 (63.3) |
| Gastrointestinal |
1 (3.3) |
4 (13.3) |
12 (40.0) |
13 (43.3) |
| General and |
0 |
5 (16.7) |
9 (30.0) |
10 (33.3) |
| injection site | ||||
| Neurological |
0 |
0 |
3 (10.0) |
3 (10.0) |
| Metabolic and nutritional |
0 |
1 (3.3) |
1 (3.3) |
2 (6.7) |
| Infections |
0 |
1 (3.3) |
0 |
1 (3.3) |
| Skin and subcutaneous tissue |
0 |
0 |
1 (3.3) |
1 (3.3) |
| Ear and labyrinth |
0 |
0 |
1 (3.3) |
1 (3.3) |
| Renal/urinary tract |
0 |
1 (3.3)a |
0 |
1 (3.3) |
| Reproductive system and breast |
0 |
0 |
1 (3.3) |
1 (3.3) |
| Vascular | 0 | 0 | 1 (3.3) | 1 (3.3) |
Data are number (%) of patients.
aEvent was serious AE (acute renal failure) but resolved without sequelae.